Abstract
The clinical use of circulating biomarkers for primary graft dysfunction (PGD) after lung transplantation has been limited. In a prospective single-center cohort, we examined the use of plasma protein biomarkers as indicators of PGD severity and duration after lung transplantation. The study comprised 40 consecutive lung transplant patients who consented to blood sample collection immediately pretransplant and at 6, 24, 48, and 72 h after lung transplant. An expert grader determined the severity and duration of PGD using the 2016 ISHLT consensus guidelines. A bead-based multiplex assay was used to measure 27 plasma proteins, and ELISA was used to measure cell injury markers including M30, M65, sRAGE, and PAI-1. Pairwise comparisons identified a robust plasma protein expression signature for PGD severity. Differential perioperative expression of IP-10, MIP1B, RANTES, IL-8, IL-1Ra, G-CSF, and PDGF-BB correlated with PGD3 development at T48-72 h. Our findings suggest that unique inflammatory protein expression patterns may be informative of PGD severity and duration, potentially improving early detection and clinical monitoring.
Introduction
Primary Graft Dysfunction (PGD) is the leading cause of early morbidity and mortality following lung transplantation. It is a severe form of acute lung injury triggered by ischemia-reperfusion—the damage caused when blood flow returns to the donor lung after oxygen deprivation. Currently, clinicians grade PGD based on oxygenation levels and chest X-rays, which are "lagging indicators" that describe damage only after it has occurred. This study seeks to identify "molecular breadcrumbs" (biomarkers) in the blood to predict PGD severity and duration earlier than current clinical standards allow.
Methods
The study followed a prospective cohort of 40 consecutive lung transplant patients at Baylor St. Luke’s Medical Center. Researchers collected plasma at five critical time points: pre-transplant (baseline) and at 6, 24, 48, and 72 hours post-reperfusion.
- Biomarker Measurement: 27 proteins (cytokines, chemokines, and growth factors) were measured via multiplex bead-based assay, and 4 cell-injury markers (M30, M65, sRAGE, and PAI-1) were measured via ELISA.
- Statistical Analysis: The team employed Linear Models for Microarray Data (LIMMA) to handle differential expression across PGD severity levels and Linear Mixed Modeling (LMM) with overlap weighting to adjust for potential confounders like BMI and the use of Extracorporeal Life Support (ECLS).
Key Results
Of the 40 patients, 55% experienced severe PGD (Grade 3) at some point, and 30% suffered from persistent PGD3 (lasting 48–72 hours). The analysis identified a robust predictive signature including IP-10, MIP-1B, RANTES, IL-8, IL-1Ra, G-CSF, and PDGF-BB that correlated strongly with the development of persistent PGD3.
Key Insights and Ideas
- IP-10 and IL-1Ra as Early Indicators: Interferon gamma-induced protein 10 (IP-10) and Interleukin-1 receptor antagonist (IL-1Ra) emerged as the most robust early markers, showing significant elevation as early as 6 hours post-transplant in patients who eventually developed persistent PGD3.
- The Pre-Transplant Paradox: Patients who developed severe PGD actually showed lower baseline levels of certain inflammatory markers (like IL-8 and RANTES) before surgery. This suggests that the "delta"—the sudden surge of these proteins during reperfusion—is a more critical predictor than absolute concentration.
- Phased Biological Process: The marker M30 (indicating apoptosis) showed a gradual rise in severe PGD patients, peaking late. This suggests that PGD is a phased process that might be interruptible with targeted therapy.
Discussion and Limitations
The primary limitation of this study is its single-center, small-sample nature (N=40). While the statistical methods were rigorous, the findings require validation in larger, multi-center trials. However, the high-resolution temporal sampling provided a detailed look at protein evolution. Moving toward a standardized biomarker panel could enable real-time monitoring and personalized "precision medicine" in the transplant ICU, allowing clinicians to detect PGD earlier and monitor treatment efficacy more accurately.
Summary updated